Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2015-02, Vol.38 (2), p.e15-e17
Hauptverfasser:	Laakso, Markku, Rosenstock, Julio, Groop, Per-Henrik, Barnett, Anthony H, Gallwitz, Baptist, Hehnke, Uwe, Tamminen, Ilkka, Patel, Sanjay, von Eynatten, Maximilian, Woerle, Hans-Juergen
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetic Nephropathies - drug therapy Dipeptidyl-Peptidase IV Inhibitors - administration & dosage Dipeptidyl-Peptidase IV Inhibitors - adverse effects Double-Blind Method Drug Therapy, Combination Female Glycated Hemoglobin A - metabolism Humans Hypoglycemia - chemically induced Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Linagliptin Male Purines - administration & dosage Purines - adverse effects Quinazolines - administration & dosage Quinazolines - adverse effects Sulfonylurea Compounds - administration & dosage Sulfonylurea Compounds - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!